Please assess the completion status of the following clinical trial:

Trial Title: Optimal Stent Selection for the Femoropopliteal Artery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects eligible for participating in this study are patients with severe PAD who have:~  1. endovascular repair of their femoropopliteal artery~ 2. standard pre-operative contrast-enhanced thin-section CTA of the lower extremities~ 3. intraoperative angiograms and blood pressure measurements proximal and distal to the stent during the endovascular repair~ 4. no aneurysmal disease of the target femoropopliteal artery~ 5. no prior open or endovascular repair of the target femoropopliteal artery (patients with re-interventions are not eligible)~ 6. at least 2 out of 3 patent crural outflow vessels~ 7. life expectancy \>6 months~ 8. no iodinated contrast allergy~ 9. creatinine less than 1.6 g/dL (unless on chronic dialysis, dialysis patients are eligible)~ 10. no orthopedic prostheses in the region of interest~ 11. ability to comply with 6-12-month follow-up contrast enhanced thin-section CTA~Exclusion Criteria:~1. no endovascular repair of the femoropopliteal artery~2. endovascular or open re-intervention in the target limb~3. no pre-operative thin-section contrast-enhanced CTA of the target limb~4. no intraoperative angiogram or blood pressure measurements proximal and distal to the stent~5. aneurysmal disease of the target femoropopliteal artery~6. less than 2 patent crural outflow vessels~7. life expectancy ≤ 6 months~8. iodinated contrast allergy~9. orthopedic prosthesis in the region of interest~10. creatinine greater than 1.6 g/dL (unless dialysis patient, chronic dialysis patients are eligible)~11. inability to comply with 6-12-month contrast-enhanced CTA follow-up requirement~12. patient belongs to vulnerable population, i.e. pregnant women, prisoners, institutionalized individuals

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Peripheral artery disease patients (Type: None): Patients with peripheral artery disease who were treated with a stent as part of their standard of care. Patients who meet the inclusion criteria (i.e. already have a stent in their femoropopliteal artery) will be consented after their endovascular repair, and those who choose to participate in the study will be followed for 6-12 months. During the follow-up, a post-operative contrast-enhanced CTA of the lower extremities will be obtained to assess for restenosis.

Based on this trial design, predict the completion outcome and termination type (if applicable).